Antiepileptic drug review: Part 2

Surgical Neurology

Volumn 49, Issue 5, 1998, Pages 566-568

  Winkler, Susan R ^a   Luer, Mark S ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; EPOXIDE; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; PRODRUG; TOPAMOX; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ATAXIA; CONFUSION; DIPLOPIA; EPILEPSY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEPHROLITHIASIS; PARESTHESIA; PRURITUS; RASH; REVIEW; SOMNOLENCE; THROMBOCYTOPENIA; VERTIGO;

EID: 0032079860     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(97)00224-3     Document Type: Article

References (13)

1. 1. Carter-Wallace felbatol should stay on market as second-line therapy; FDA committee recommends boxed warning for aplastic anemia, liver failure. FDC Reports - "The Pink Sheet" 1994;56:3-4.
2. 2. Felbamate Package Insert. Cranbury, New Jersey: Wallace Laboratories, July 1993.
3. 3. Jamerson BD, Dukes GE, Brouwer KLR, et al. Venous irritation related to intravenous administration of phenytoin vs. fosphenytoin. Pharmacotherapy 1994; 14:47-52.
4. 4. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology 1990;40:456-60.
5. 5. Schmidt D. Potential antiepileptic drugs: gabapentin. In: Levy RH, Mattson RH, Meldrum BS, Penry JK, Dreifuss FE, eds. Antiepileptic drugs, third edition. New York: Raven Press, Ltd., 1989:915-35.
6. 6. Vollmer KO, Turck D, Brockbrader HN, et al. Summary of neurontin (gabapentin) clinical pharmacokinetics (abstract). Epilepsia 1992;33 (Suppl 3):77.
7. 7. Leach MJ, Baxter MG, Critchley MAE. Neurochemical and behavioral aspects of lamotrigine. Epilepsia 1991;32 (Suppl 2):S4-S8.
8. 8. Yau MK, Adams MA, Wargin WA, Lai AA. A single-dose and steady-state pharmacokinetic study of lamotrigine in healthy male volunteers. Proceedings of the Third International Cleveland Clinic-Bethel Epilepsy Symposium. Cleveland, June 1992.
9. 9. Goa KL, Ross SR, Crisp P. Lamotrigine. Drugs 1993;43: 152-76.
10. 10. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991;32 (Suppl 2):S17-S21.
11. 11. White HS, Brown SD, Skeen GA, et al. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride channels (abstract). Epilepsia 1996;36(Suppl 3):S39.
12. 12. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons (abstract). Epilepsia 1995;36 (Suppl 4):38.
13. 13. Shorvon S. Safety to topiramate: adverse events and relationship to dosing. Epilepsia 1996;37(Suppl 2): S18-S22.